Sagimet Biosciences Inc. Series A Common Stock SGMT

Sagimet Biosciences Inc. es una empresa biofarmacéutica en fase clínica. La empresa se dedica al desarrollo de terapéuticas llamadas inhibidores de la sintasa de ácidos grasos (FASN) que apuntan a vías metabólicas disfuncionales en enfermedades resultantes de la sobreproducción del ácido graso, palmitato. El candidato a fármaco principal de la empresa, denifanstat, es una pastilla oral de una vez al día y un inhibidor selectivo de FASN en desarrollo para el tratamiento de la esteatohepatitis no alcohólica (NASH). Además de NASH, la empresa está evaluando denifanstat en el acné y en formas selectas de cáncer, áreas de enfermedad en las que la desregulación del metabolismo de ácidos grasos también juega un papel clave. Denifanstat se está probando en un ensayo clínico de fase II para el acné vulgar moderado a severo, y en un ensayo de fase III para el glioblastoma multiforme recurrente (GBM) en combinación con bevacizumab.

• GlobeNewswire Inc. 28 sept

  Acne Vulgaris Market Set for Significant Growth During the Forecast Period (2026–2036), Amid Rising Disease Burden and Therapeutic Advances | DelveInsight

  The acne vulgaris market is expected to grow steadily through 2036, driven by increasing disease prevalence affecting 85% of adolescents and young adults, and a pipeline of emerging therapies. Key players including Ascletis Pharma, Sagimet Biosciences, AOB Pharma, and Kintor Pharmaceutical are developing novel treatments like Denifanstat (ASC40), TVB-3567, B244, and GT20029 to address unmet needs in moderate-to-severe and treatment-resistant acne. The U.S. holds the largest market share, with recent approvals including clascoterone (WINLEVI) and combination therapy CABTREO expanding treatment options.

  

• GlobeNewswire Inc. 25 ago

  Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial of Denifanstat in Acne Toward Patient Enrollment in Q4 2026

  Sagimet Biosciences announced that its AURORA Phase 3 clinical trial of denifanstat, a FASN inhibitor for moderate to severe acne, is on track to begin patient enrollment in Q4 2026. All clinical trial sites have been identified and a CRO has been retained, with patient screening expected to start in October 2026. The trial will enroll approximately 800 U.S. patients, including 450 adolescents, and if approved, denifanstat would be the first innovative oral acne treatment in over 40 years.

  

• GlobeNewswire Inc. 29 jun

  Sagimet Biosciences Joins the Russell 2000® and Russell 3000® Indexes

  Sagimet Biosciences Inc. (Nasdaq: SGMT) announced its inclusion in the Russell 3000 and Russell 2000 indexes effective June 29, 2026. The clinical-stage biopharmaceutical company plans to initiate a Phase 3 clinical trial of denifanstat for moderate to severe acne in the second half of 2026. The company has sufficient capital to fund operations through 2028, including the denifanstat Phase 3 trial data readout.

  

• GlobeNewswire Inc. 22 jun

  Sagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

  Sagimet Biosciences announced management participation in the Leerink Partners Therapeutics Forum on July 15, 2026. The company also approved an inducement grant of 34,300 stock options to two newly hired employees as part of their employment compensation packages.